Camp4 Registers Resale of 32.7M Shares from $50.1M Private Placement, Representing 38.6% of Outstanding
CAMP has more than doubled off its 52-week low of $1.32 on elevated volume (3.2× avg).
Summary
Camp4 Therapeutics registered the resale of 32.7 million shares from its recent $50.1 million private placement, creating a significant tradable overhang equal to 38.6% of outstanding shares.
Key Events · Financing and Capital Events · CAMP
-
Resale Registration Filed
An S-3 was filed to register the resale of 10,795,804 common shares and 21,925,368 shares underlying pre-funded warrants, all issued in the August 3, 2026 second closing of the private placement.
-
Significant Overhang Created
Assuming exercise of the pre-funded warrants, the registered shares represent approximately 38.6% of total outstanding common stock as of August 3, 2026, creating a large potential supply overhang.
-
Follows Recent $50.1M Financing
The registration covers shares from the second closing of a private placement that raised $50.1 million in gross proceeds, with shares sold at $1.53–$1.65 per share—well below the current $4.50 stock price.
-
No Proceeds to Company
Camp4 will not receive any proceeds from the resale of these shares; it may receive nominal proceeds if pre-funded warrants are exercised for cash at $0.0001 per share.
Analysis · CAMP · Life Sciences
Just three days after the second closing of its private placement, Camp4 filed an S-3 to register the resale of 32.7 million shares—10.8 million common shares and 21.9 million shares underlying pre-funded warrants. That block represents approximately 38.6% of the company's outstanding common stock. While the $50.1 million raised extends the cash runway for lead program CMP-002, making this overhang immediately tradable could pressure the stock. The filing fulfills a contractual obligation under the September 2025 registration rights agreement.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAMP was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $233.7M. The 52-week trading range was $1.32 to $7.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.